29 January 2024 - Approval supported by Phase 3 ADVANCE-CIDP open-label study data demonstrating safety and efficacy as an intravenous therapy for adults with CIDP.

Takeda today announced that the US FDA has approved Gammagard Liquid [immune globulin infusion (human) 10% solution] as an intravenous immunoglobulin therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy.

Read Takeda press release